18th May 2017

 

Barts Health NHS Trust signs seven year contract with Roche Diagnostics Ltd to transform

London’s laboratories

Roche Diagnostics Ltd is delighted to announce that it has been awarded a seven year contract by Barts Health NHS Trust to transform its laboratory services across London. The investment, which follows a competitive tender process, will see laboratories at St Bartholomew's Hospital, The Royal London Hospital, Whipps Cross University Hospital and Newham University Hospital upgraded to benefit from the latest in advanced automation. The Trust sought a partner with the skills and experience to enhance and upgrade the existing laboratories; Roche Diagnostics Ltd was awarded the contract due to its ability to provide new instrumentation, advanced automation and a managed service in a number of medical disciplines across all four sites.

ENDS

For more details please contact:  roche@fourcommunications.com

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.